The author wishes to make the following corrections to this paper \[[@B1-molecules-23-01438]\]. Due to our oversight, the title of article \[[@B1-molecules-23-01438]\] was same as that of article \[[@B2-molecules-23-01438]\]. Because our research ideas and methods were different from those of article \[[@B2-molecules-23-01438]\], we did not list it as a reference study in the article \[[@B1-molecules-23-01438]\]. We would like to offer our sincere apologies to all of the authors of the article \[[@B2-molecules-23-01438]\], who were Addla Dinesh, Jallapally Anvesh, Kanwal Abhinav, Sridhar Balasubramanian, Banerjee Sanjay K., and Kantevari Srinivas.

The corrections include: (1) replacing the title "Design, Synthesis, and Evaluation of Novel 2-Hydroxypyrrolobenzodiazepine-5,11-dione Analogues as Potent Angiotensin Converting Enzyme (ACE) Inhibitors" with "Design, Synthesis, and Evaluation of Novel Phenolic acid/Dipeptide/Borneol Hybrids as Potent Angiotensin Converting Enzyme (ACE) Inhibitors with Anti-hypertension Activity"; and (2) replacing "2-hydroxypyrrolobenzodiazepine-5,11-dione analogues" with "phenolic acid/dipeptide/borneol hybrids" in the abstract.

The authors would like to apologize for any inconvenience caused to the readers by these changes.
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